Immune System Diseases
The immune system is a highly intricate and sophisticated defense mechanism that safeguards the body against foreign pathogens, including viruses, bacteria, and parasites. Despite its remarkable efficiency, the immune system can occasionally experience dysregulation, resulting in immune system diseases. Our company stands at the forefront of pioneering research and development of drugs and therapies specifically designed to address these complex immune disorders.
Overview of Immune System Diseases
Immunological disorders, commonly known as immune system diseases or autoimmune diseases, encompass a diverse array of conditions wherein the immune system erroneously targets and attacks healthy cells and tissues within the body. This misguided immune response can impact multiple organs and systems, giving rise to a wide range of symptoms and complications. Well-known examples of immune system diseases include rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease.
Pathogenesis of Immune System Diseases
- Genetic Predisposition
Genetic predisposition can play a significant role in the development of immune system diseases. Family history is often a crucial factor, as certain disorders tend to occur within families. These genetic factors contribute to the dysfunction of the immune system and can influence the likelihood of an individual developing an immune system disease.
- Environmental Triggers
Various environmental factors can contribute to the dysregulation of the immune system. Infections, exposure to toxins, and certain medications are among the triggers that can disrupt the normal functioning of the immune system. Viral or bacterial infections, in particular, have the potential to induce an abnormal immune response, especially in individuals with genetic susceptibility.
- Hormonal Imbalance
Hormonal changes, particularly in women, have been linked to the onset or exacerbation of immune system diseases. Fluctuations in estrogen levels, such as those occurring during pregnancy or menopause, may influence immune system activity and contribute to disease development.
Fig.1 Evidence for involvement of the immune system in PD. (Tan, Eng-King, et al., 2020)Targets for Immune System Diseases Therapy Development
Immunomodulatory Therapies
Immunomodulatory therapies aim to regulate and rebalance the immune system. This category includes drugs such as corticosteroids, which suppress immune system activity, and disease-modifying anti-rheumatic drugs (DMARDs), which slow disease progression in conditions like rheumatoid arthritis.
Biologic Therapies
Biologic therapies utilize genetically engineered proteins or monoclonal antibodies to target specific immune system components. These therapies, such as TNF inhibitors or B-cell-targeted therapies, have revolutionized therapeutic development of immune system diseases.
Cell-Based Therapies
Cell-based therapies involve the use of cells, such as stem cells or immune cells, to modulate the immune response. These therapies hold promise in conditions like multiple sclerosis, where the transplantation of autologous stem cells can help regenerate damaged tissue and restore immune system balance.
Gene Therapies
Gene therapies aim to correct genetic abnormalities or modulate gene expression to treat immune system diseases. This cutting-edge approach holds great potential for disorders with a strong genetic component, allowing for precise and personalized therapy strategies.
Our Services
Developing effective drugs and therapies for immune system diseases requires specialized knowledge and advanced equipment. Our company has the capabilities and platforms to serve you in improving immune system diagnostics and therapeutic development.
Rare Types of Digestive System Diseases
| A-G | |
| Acute Graft Versus Host Disease (Acute GVHD) | Alstrom Syndrome (ALMS) |
| Aicardi-Goutieres Syndrome (AGS) | Amyloid Light-chain Amyloidosis (AL-amyloidosis) |
| Autoimmune Encephalitis (AE) | Catastrophic Antiphospholipid Syndrome (CAPS) |
| Cutaneous Lupus Erythematosus (CLE) | Graves disease (GRD) |
| Erdheim-Chester Disease (ECD) | Guillain-Barre Syndrome (GBS) |
| H-M | |
| Hereditary Angioedema (HAE) | Hyper IgE Syndrome (HIES) |
| Immune Thrombocytopenic Purpura (ITP) | Kawasaki Disease (KWD) |
| Macrophage Activation Syndrome (MAS) | Myelopathy, Htlv-1-Associated (HAM) |
| P-W | |
| Paroxysmal Nocturnal Hemoglobinuria (PNH) | Post-Transplant Lymphoproliferative Disease (PTLD) |
| Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency (ADA-SCID) | Systemic Mastocytosis (SMCD) |
| Systemic Lupus Erythematosus (SLE) | Systemic Sclerosis (SSc) |
| Temporal Arteritis (TA) | Tularemia |
| Waldenstroem's Macroglobulinemia (WM) | Wiskott-Aldrich Syndrome (WAS) |
Therapy Development Platforms
At our company, we specialize in formulating and optimizing drug candidates to enhance their bioavailability, stability, and therapeutic efficacy. Our advanced drug delivery systems ensure precise and targeted delivery of therapeutic agents to the affected tissues. We provide custom animal model development services as well as a full suite of preclinical research services, including drug safety evaluation and pharmacokinetic analysis.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.References
- Tan, Eng-King, et al. "Parkinson disease and the immune system—associations, mechanisms and therapeutics." Nature Reviews Neurology 16.6 (2020): 303-318.
- Baldovino, Simone, et al. "Immunological rare diseases." Rare diseases epidemiology: update and overview (2017): 497-509.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
